

Eurofins Genomics expands Sanger sequencing capabilities with the acquisition of LGC's Sanger sequencing operations

[Berlin, 16 April 2025] – Eurofins Genomics has acquired the Sanger sequencing business of LGC Group, a leading global life sciences tools company. The acquisition enhances Eurofins Genomics' offering in the Sanger sequencing market and supports its ambition to offer a comprehensive portfolio of genomic services to its clients.

With a long-standing track record and deep expertise in Sanger sequencing, LGC's business has built a strong reputation for quality and service. The integration of LGC's Sanger sequencing capabilities into the Eurofins Genomics portfolio will enhance Eurofins Genomics' service offerings and expand capacity.

This strategic acquisition further enables Eurofins Genomics to deliver high-quality results, excellent service, fast turnaround times and innovative solutions, which include Next-Generation Sequencing (NGS), Array Genotyping, Oligo and Gene Production, and a super-express Whole-Plasmid Sequencing Service, to its valued client base.

Eurofins Genomics remains committed to delivering innovation, quality, and service and to meeting the evolving needs of the genomics market through continued investment in expertise and infrastructure.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agrosience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With ca. 63,000 staff across a network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Scientific SE shares are listed on Euronext Paris Stock Exchange.